We selected a set of targets to interrogate the immune tumor microenvironment 7: T cells (CD4, CD8), B-cells (B220), myeloid cells including dendritic cells (CD11b, MHC II, CD11c) and functional ...
CD4/MHC Class II, CD8/MHC Class I). Pathogenic Steps Inhibited by Efalizumab: (a) T-cell activation by antigen in the lymph nodes, (b) T-cell binding to the endothelium with migration into the ...